Story
Novartis Beats Q2 Profit Forecasts But Reaffirms Cautious Full-Year Outlook

Swiss drugmaker Novartis AG reported second-quarter earnings that surpassed analyst expectations on Tuesday but maintained its full-year forecast, signaling that temporary benefits from the period will reverse as spending increases in the second half of the year.
The company's shares rose as much as 3% following the announcement.
Profit Beat Driven by Temporary Factors
Novartis posted a quarterly core operating profit of $5.94 billion, significantly ahead of the $5.31 billion average analyst forecast cited by Visible Alpha. The company attributed the strong performance to temporary sales and cost benefits that boosted core operating profit by about 5%.
According to Chief Financial Officer Mukul Mehta, these one-time effects are expected to reverse later in the year. The quarter was also helped by a 6% decline in core selling, general, and administrative (SG&A) expenses to $3.24 billion, which the company linked to productivity gains. Quarterly sales saw a 1% rise in constant currency to $14.41 billion.
Cautious Outlook Amid Patent Cliff
Despite the strong quarter, Novartis reaffirmed its full-year guidance for low-single-digit sales growth and a low-single-digit decline in core operating profit. Analysts noted that the beat did not trigger a guidance upgrade because the timing of cost spending had shifted within the year, with higher research and launch-related expenses anticipated in the third and fourth quarters.
AdThe cautious outlook comes as Novartis navigates a significant period of patent expiries, most notably for its blockbuster heart drug Entresto. Sales for Entresto fell 50% to $1.18 billion due to generic competition in the U.S., a steeper decline than analysts had forecast. The company expects Entresto sales to fall by approximately $4 billion this year.
Pipeline in Focus for Future Growth
While Entresto sales declined, Novartis saw strong growth from other key products, offsetting the impact:
- Kisqali (breast cancer drug): Sales rose 44% to $1.7 billion.
- Scemblix (leukemia treatment): Sales nearly doubled to $562 million.
- Cosentyx (psoriasis drug): Sales grew 12% to $1.82 billion, aided by a U.S. stocking benefit of about $100 million.
Investors are now closely watching for late-stage trial results for three experimental drugs, which represent an estimated $10 billion in peak annual sales potential. Chief Executive Vas Narasimhan told reporters that results for pelacarsen, remibrutinib, and del-desiran should arrive in the coming months, expressing confidence in the company's internal pipeline over the need for large-scale acquisitions.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.